Alzamend Neuro Inc. (ALZN)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Alzamend Neuro (ALZN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?
Here is how Alzamend Neuro, Inc. (ALZN) and Beam Therapeutics Inc. (BEAM) have performed compared to their sector so far this year.
Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details
Monday, Alzamend Neuro Inc. ALZN stock is trading higher after the company partnered with Massachusetts General Hospital as its contract research organization.
Alzamend Neuro Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 4 | $4 | $4.84 | $0.84 | 21% |
Alzamend Neuro Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| EW Edward Woo Ascendiant Capital | -1,185.33 | $1,590.11 | $1,434.25 | $155.86 | 9.8% |
Alzamend Neuro Inc. (ALZN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alzamend Neuro Inc. ever had a stock split?
Alzamend Neuro Inc. Profile
| Biotechnology Industry | Healthcare Sector | Stephan Jackman CEO | NASDAQ (CM) Exchange | 02262M605 CUSIP |
| US Country | 4 Employees | - Last Dividend | 12 May 2025 Last Split | - IPO Date |
Overview
Alzamend Neuro, Inc., established in 2016 and based in Atlanta, Georgia, operates as a clinical-stage biopharmaceutical enterprise dedicated to confronting neurodegenerative and psychiatric conditions through innovative therapeutic solutions. Its commitment spans the rigorous development of novel products aiming to address a variety of mentally debilitating conditions. Through strategic partnerships, including a notable agreement with Massachusetts General Hospital for the Phase II clinical trial of one of its key products, Alzamend Neuro, Inc. seeks to forge ahead in the biotechnology sphere, positioning itself as a beacon of hope for patients suffering from these challenging diseases.
Products and Services
- AL001:
- ALZN002:
This product signifies a therapeutic composite combining lithium, proline, and salicylate, designed to treat a range of disorders including Alzheimer's, bi-polar disorder, major depressive disorder, post-traumatic stress disorder, other neurodegenerative diseases, and various psychiatric conditions. By integrating these components, AL001 aims to offer a multifaceted approach to managing symptoms and improving the quality of life for those affected by these serious conditions.
The innovative approach of ALZN002 lies in its use of a method that employs a mutant-peptide sensitized cell as a cell-based therapeutic vaccine. This advance seeks to rejuvenate a patient’s immune system, empowering it to combat Alzheimer's disease more effectively. This cell-based therapeutic vaccine represents a revolutionary step in the treatment of Alzheimer's by potentially halting or reversing the progress of the disease through immunological intervention.
